Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) inhibition was proposed to alter alpha-synuclein pathology, whereby in PD mutations in this protein may be detrimental (familial forms) or reduce risk [128, 129]. Here, SNCA is linked to Parkinson disease.